• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA chief: Changing generics regulations could reel in drug prices

May 25, 2017 By Sarah Faulkner

FDAPart of the FDA commissioner’s job is to oversee the federal regulatory watchdog as it evaluates pharmaceuticals for safety and efficacy. Most FDA chiefs have avoided the topic of drug prices, given that it isn’t a clearly-stated part of the agency’s mission

But just 2 weeks into the job, newly-confirmed FDA commish Dr. Scott Gottlieb proposed a plan, called the Drug Competition Action Plan, that he believes will help restrain the cost of prescription drugs.

As he testified before the House appropriations subcommittee that’s deciding the FDA’s 2018 fiscal budget, Gottlieb said that helping generics gain access to the market could bring down the prices for expensive brand name pharmaceuticals.

“Simply put, too many patients are priced out of the medicines they need,” Gottlieb said, according to The Wall Street Journal. “While the FDA does not have a direct role in drug pricing, we can take steps to facilitate entry of lower-cost alternatives to the market, and increase competition.”

The commissioner called on the FDA to accelerate the application review process to eliminate the backlog of 2,640 applications. Nearly 1,500 of those applications have been sent back to sponsors with requests for changes.

Gottlieb also suggested that the FDA could regularly publish lists of older medicines that don’t have generic competition, to encourage generics-makers into the market.

Under current FDA standards, it’s challenging to prove equivalence to “complex” drugs, like medications administered using an inhaler. Because of this, there are a number of products that are off patent but still don’t have generic competition – including Mylan‘s (NSDQ:MYL) EpiPen. Gottlieb said the FDA could make the review process simpler in order to get generics to the market.

He also said the agency should intervene in cases in which a brand-name drugmaker is accused of using FDA rules to refuse to make a drug available to generic manufacturers.

“The FDA has an important role to play in making sure that its statutory and regulatory processes are working as intended, and not being manipulated in ways that FDA and Congress did not intend,” he said.

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy Tagged With: Mylan

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS